Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Abstract

Department of Medical Oncology, Royal North Shore Hospital, Sydney University, Sydney, Australia Correspondence to: Nick Pavlakis. Royal North Shore Hospital, St Leonards 2065 NSW Australia. Email: nick.pavlakis@sydney.edu.au. Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Dr. Song Xu (Department of lung cancer surgery, Tianjin Medical University General Hospital; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin, China). Comment on: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol 2019;37:2518-27.